Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study from the February 2009 issue of the British Journal of Ophthalmology.
Please click here to read the full story.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.